Pharma Compliance in India: From DPCO to FDC Bans - A Legal Framework Review Examining Prosecution Trends, Regulatory Gaps, and Recent Judgments Impacting the Indian Pharmaceutical Industry

New Delhi [India], July 7: The Compliance Conundrum in Indian Pharma India’s pharmaceutical sector commands global recognition for its dominance in generic drug manufacturing and affordability. However, beneath this success lies a maze of legal and regulatory frameworks, split between central and state oversight. From the Drug Price Control Orders (DPCO) to sweeping bans on Fixed-Dose Combinations (FDCs), pharmaceutical compliance is no longer just a matter of procedure—it has become a legal battlefield.

This article delves into the evolving contours of pharma regulation, prosecution patterns, and recent judicial decisions, with a spotlight on pricing controls, FDC bans, misbranding charges, and intellectual property conflicts.

I. Drug Price Control: Walking the Legal Tightrope The Drug Price Control Order (DPCO), 2013, under the Essential Commodities Act, 1955, grants the National Pharmaceutical Pricing Authority (NPPA) powers to regulate prices of essential medicines. While designed to ensure affordability, the DPCO has increasingly triggered legal scrutiny from the industry.

Key Legal Flashpoints: - Trade Margin Rationalization: Bringing non-scheduled drugs under price control indirectly has invited constitutional challenges under Article 19(1)(g)—the right to trade and profession. - Retrospective Pricing Notifications: These often lead to disputes over arbitrary cost ceilings.

Case Insight: In Baxter India Pvt. Ltd. v. Union of India (2023), the Delhi High Court stayed NPPA’s price fixation for certain medical devices, citing the absence of a transparent pricing methodology.

II. Substandard & Misbranded Drugs: Navigating Criminal Prosecution Under the Drugs and Cosmetics Act, 1940, the manufacture or sale of misbranded, substandard, adulterated, or spurious drugs is a punishable offense.
Offense Classifications: - Section 17: Misbranded drugs - Section 17A/B/C: Adulterated, substandard, or spurious drugs

Yet, many prosecutions arise from minor technical deviations: - Variations in active pharmaceutical ingredient (API) levels - Labeling errors with no actual harm - Batch failures despite GMP-compliant manufacturing

Legal Safeguards Available: - Section 34(2): Exempts directors/officers if they prove due diligence and lack of knowledge. - Section 19(3): Protects licensed retailers sourcing from authorized distributors. - Lab Test Reliability: Defense often contests findings from state-run labs, demanding retesting in CDSCO-recognized labs due to inconsistency.

Persistent Challenges: Jurisdictional Overlap - CDSCO and State Licensing Authorities (SLAs) often clash, resulting in procedural ambiguity. - Defective Show-Cause Notices: Courts have repeatedly quashed notices lacking scientific rationale or procedural adherence. - FDC Cases: Increasingly, courts demand data-backed scientific justification over regulatory formalities alone.

IV. Fixed-Dose Combinations (FDCs): The Judicial Balancing Act FDCs—combinations of two or more drugs—have been at the center of legal and regulatory strife.

Regulatory Action: In 2016, the Centre banned 344 FDCs, citing a lack of therapeutic rationale.

Pharma companies challenged these bans, arguing: - Approvals by State Authorities were overlooked. - CDSCO did not consult stakeholders or evaluate clinical efficacy.

Landmark Ruling: In Union of India v. Pfizer Ltd. & Others (2023), the Supreme Court upheld the bans, validating the Centre’s power under Section 26A, provided: - Expert consultation is conducted - Public health rationale is recorded - Procedural fairness is ensured

V. Intellectual Property in Pharma: Public Health vs. Patents Indian courts tread cautiously between patent rights and medicine accessibility, especially in the post-TRIPS era.

Key Legal Trends: - Compulsory Licensing: Seen in Natco v. Bayer, where access to cancer medication was prioritized. - Section 3(d): Bars evergreening of existing drugs by requiring enhanced efficacy for new patents. - Trademark Conflicts: Litigation over similar-sounding drug names has risen, especially when patient safety is at stake.

Courts have consistently emphasized public interest in essential drugs, often placing access above exclusivity.

Conclusion: The Road Ahead — From Reactive to Proactive Compliance India’s pharmaceutical regulatory framework is a paradox of strong enforcement but fragmented execution. With companies caught between regulatory oversight, legal prosecution, and compliance fatigue, it is imperative to move toward a more harmonized, science-led legal ecosystem.

The Way Forward: - Centralized Compliance Architecture: Reduce friction between CDSCO and SLAs. - Scientific Integrity in Enforcement: Incorporate data-backed decision-making. - Judicial Oversight on Overreach: Strengthen checks on procedural arbitrariness.

As India cements its position as a global pharmaceutical powerhouse, its legal and regulatory machinery must evolve from reactive compliance to transparent, predictable, and evidence-driven regulation.
Advocate Srijan Tiwari is a practicing counsel at the Delhi High Court, specializing in pharmaceutical law, healthcare regulation, and constitutional litigation.